Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-HeFH
2020-004390-44Phase 3Completed
- Sponsor
- LIB Therapeutics, LLC
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Lerodalcibep monthly with Placebo monthly (2 arms). Primary endpoints: Percent change from baseline in LDL-C at Week 24 and Percent change from baseline in LDL-C at mean of Weeks 22 and 24. Started May 2021; status: completed.
02
Drugs
lerodalcibep
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2020-004390-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004390-44.